Is This Big News for Arena Pharmaceuticals?
Oct 17th 2012 3:00PM
Updated Oct 17th 2012 3:10PM
Arena Pharmaceuticals (NAS: ARNA) gained approval from the Food and Drug Administration for its obesity drug, Belviq, this summer, and now it's gearing up to market the drug with its partner Eisai. Arena has a lot riding on a successful Belviq launch, but the company is also developing other drugs. For instance, it recently announced a second phase 1 clinical trial for its developmental pulmonary arterial hypertension drug, APD811.
What effect did this news story have on Arena's share price? What does the development of APD811 mean for Arena for both the short and long term? Also, if the drug eventually makes it through phase 1, 2, and 3 clinical trials, will Arena face competition from companies like United Therapeutics (NAS: UTHR) and Gilead Sciences (NAS: GILD) in the pulmonary arterial hypertension market? In the following video, health care analysts Max Macaluso and Brenton Flynn discuss these issues.
When it comes to do-or-die business, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for Belviq. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.
The article Is This Big News for Arena Pharmaceuticals? originally appeared on Fool.com.Max Macaluso, Ph.D. and Brenton Flynn hold no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services have recommended buying shares of Gilead Sciences. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.